Neuroscience Today—April 22, 2026

This week’s Neuroscience update highlights regulatory progress, real-world evidence, support initiatives, imaging advances, and patient-centered research across neurological disorders.

In Today’s Newsletter

Dive deeper

🧠 Lundbeck highlights VYEPTI cognitive-symptom data in migraine [1] [Denmark/US • 19 Apr 2026]

https://news.cision.com/h–lundbeck-a-s/r/lundbeck-presents-new-data-at-aan-2026-highlighting-real-world-changes-in-migraine-related-cognitive,c4336771
Context: INFUSE is an ongoing real-world study in people with migraine and at least one prior anti-CGRP preventive treatment failure.
Key point: Lundbeck said patient-reported migraine-related cognitive symptoms improved over 6 months after starting VYEPTI (eptinezumab), with some improvement reported as early as Day 7.
Implication: Could inform practice and payer discussions, interpretation depends on study design and confounding control.

🏠 Teva launches Home Ground schizophrenia support platform [2] [US/Israel • 15 Apr 2026]

https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Teva-Launches-Home-Ground-Schizophrenia-Community-a-New-Online-Resource-Hub-for-People-Living-with-Schizophrenia-and-Their-Care-Partners/default.aspx
Context: The platform was developed with people living with schizophrenia, care partners, and advocacy groups.
Key point: Teva launched Home Ground Schizophrenia Community, a no-cost online hub with symptom tools, wellness resources, independent-living support, and community event information.
Implication: May expand screening, initiation, and follow-up at scale.

💊 Neurocrine posts head-to-head persistence advantage for INGREZZA [3] [US • 14 Apr 2026]

https://neurocrine.gcs-web.com/news-releases/news-release-details/neurocrine-biosciences-presents-first-real-world-head-head
Context: Retrospective U.S. IQVIA claims analysis, propensity-matched cohorts, adults with tardive dyskinesia, 6-month follow-up.
Key point: INGREZZA (valbenazine) showed higher treatment persistence than AUSTEDO XR (55.6% vs 48.1%), lower switching (7.7% vs 11.2%), and longer time to discontinuation or switch (>180 vs 129 days).
Implication: Could inform practice and payer discussions, interpretation depends on study design and confounding control.

🧬 Sumitomo Pharma wins limited Japan approval for Parkinson’s cell therapy [4] [Japan • 17 Apr 2026]

https://pmlive.com/pharma_news/sumitomo-pharmas-stem-cell-therapy-for-parkinsons-given-limited-approval-in-japan/
Context: Amchepry (raguneprocel) is a stem cell-derived dopamine neuron replacement therapy transplanted into the putamen; the cited Phase 1/2 study followed seven patients for 24 months.
Key point: Japan granted conditional and time-limited approval for Amchepry in Parkinson’s disease, with post-approval safety and efficacy data collection required over seven years.
Implication: May influence prescriber choice and payer reviews pending full data.

🩻 Bracco secures Health Canada approval for VUEWAY [5] [Canada • 17 Apr 2026]

https://www.morningstar.com/news/pr-newswire/20260417ny36993/bracco-receives-health-canada-approval-for-vueway-injection-gadopiclenol-advancing-lower-dose-mri-contrast-imaging
Context: VUEWAY (gadopiclenol) is a macrocyclic gadolinium-based contrast agent indicated for CE-MRI in adults and children 2 years and older.
Key point: Health Canada approved VUEWAY, which Bracco says can deliver diagnostic contrast enhancement at 0.05 mmol/kg, half the 0.1 mmol/kg dose used with other GBCAs.
Implication: Introduces competition that may affect pricing and formulary access.

🧪 Mapi Pharma previews GA Depot disability data in MS [6] [Israel • 16 Apr 2026]

https://www.manilatimes.net/2026/04/16/tmt-newswire/globenewswire/mapi-pharma-to-present-efficacy-edss-data-from-glatiramer-acetate-depot-long-acting-injection-studies-in-relapsing-forms-of-multiple-sclerosis-rms-and-primary-progressive-multiple-sclerosis-ppms-at-aan-2026/2322120
Context: EDSS results came from a Phase IIa PPMS study (n=30) and a pivotal Phase III RMS study (n=1,016 total; 508 active-arm).
Key point: Mapi said once-monthly intramuscular GA Depot showed EDSS stabilization in RMS and PPMS, suggesting potential to slow disability progression.
Implication: May influence prescriber choice and payer reviews pending full data.

🧠 Evaxion extends AI-Immunology into glioblastoma vaccine design [7] [Denmark/US • 17 Apr 2026]

https://evaxion.ai/investors/press-releases/?press_release_id=11091
Context: The work, conducted with Duke University School of Medicine, focused on endogenous retrovirus-derived antigens and neoantigens in glioblastoma samples.
Key point: Evaxion said its AI-Immunology platform identified ERV-derived antigens and vaccine-design opportunities for glioblastoma, a tumor type with low mutational burden.
Implication: Signals pipeline investment and modality expansion.

🗂️ Alira Health and AiNA launch AXIS Registry in autoimmune neurology [8] [US • 15 Apr 2026]

https://finance.yahoo.com/news/alira-health-autoimmune-neurology-alliance-130000862.html
Context: AXIS is designed to capture longitudinal patient-reported and clinical data, beginning with myasthenia gravis and expanding to other autoimmune neurological diseases.
Key point: Alira Health and the Autoimmune Neurology Alliance launched the AXIS Registry to support real-world, patient-centered research and study recruitment in autoimmune neurology.
Implication: Could inform practice and payer discussions, interpretation depends on study design and confounding control.

Why it Matters

Neurology evidence generation is widening beyond classic endpoints, toward cognition in migraine, persistence in tardive dyskinesia, and patient-centered registries in autoimmune disease.
Japan’s conditional approval of raguneprocel shows regenerative neurology moving from proof-of-concept toward regulated clinical use, albeit with limited access and required follow-up.
Imaging and diagnostics remain active, with Bracco positioning lower-dose gadolinium MRI as both a safety and workflow discussion.
Platform stories matter too, Teva’s schizophrenia resource hub and Evaxion’s AI-based antigen discovery both reflect ecosystem plays beyond a single asset.
Multiple items are still conference-stage or observational, so read-through to practice will depend on fuller datasets, peer review, and regulatory follow-up.

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🎬 Watch on YouTube. Subscribe and never miss a video.

🧰 See our full range of services. Discover how we can help you.

📚 View the full Neuroscience archive on our research hub page.

FAQ

What did Lundbeck report for VYEPTI in migraine?

Lundbeck said real-world INFUSE data showed improvement in migraine-related cognitive symptoms after starting VYEPTI (eptinezumab), including “brain fog,” in patients with prior anti-CGRP preventive failure. The release cites 6-month patient-reported outcomes, with some changes seen by Day 7. [1]

How strong is the INGREZZA versus AUSTEDO XR comparison?

It is a retrospective, matched U.S. claims analysis, not a randomized head-to-head trial. Neurocrine reported better 6-month persistence and less switching for INGREZZA, but interpretation should account for observational design limits. [3]

What does Japan’s approval of Amchepry mean in practice?

Amchepry (raguneprocel) received conditional, time-limited approval in Japan for Parkinson’s disease. The authorization lasts seven years, during which Sumitomo Pharma must collect additional safety and efficacy evidence for potential full approval. [4]

What is notable about VUEWAY’s Canada approval?

Bracco positions VUEWAY (gadopiclenol) as a lower-dose macrocyclic GBCA for CE-MRI. The company says it supports effective imaging at 0.05 mmol/kg, which is lower gadolinium exposure than the 0.1 mmol/kg dose cited for other GBCAs. [5]

What is GA Depot trying to show in multiple sclerosis?

Mapi Pharma said GA Depot produced EDSS stabilization in studies spanning relapsing MS and PPMS. The current update is a conference presentation, so the practical impact will depend on fuller efficacy, safety, and regulatory details. [6]

What is the AXIS Registry built to do?

AXIS is a longitudinal registry launched by Alira Health and AiNA to collect patient-reported and clinical data in autoimmune neurology, starting with myasthenia gravis. It is also intended to support future research and recruitment into prospective studies. [8]

Entities / Keywords

VYEPTI (eptinezumab, Lundbeck, migraine, INFUSE, anti-CGRP, brain fog)
Home Ground Schizophrenia Community (Teva, schizophrenia, care partners, peer support, symptom tracking)
INGREZZA (valbenazine, Neurocrine Biosciences, tardive dyskinesia, VMAT2 inhibitor, treatment persistence)
AUSTEDO XR (deutetrabenazine, tardive dyskinesia, switching, persistence)
Amchepry (raguneprocel, Sumitomo Pharma, Parkinson’s disease, stem cell therapy, dopamine neuron replacement)
VUEWAY (gadopiclenol, Bracco Imaging, Health Canada, CE-MRI, GBCA, lower-dose gadolinium)
GA Depot (glatiramer acetate depot, Mapi Pharma, RMS, PPMS, EDSS, Copaxone)
AI-Immunology (Evaxion, glioblastoma, ERV-derived antigens, neoantigens, personalized cancer vaccine)
AXIS Registry (Alira Health, Autoimmune Neurology Alliance, AiNA, myasthenia gravis, real-world data)